Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Myofibroma × remimazolam × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Emergence Delirium 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Quality of Recovery 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myofibroma 1 Endobronchial Metastases 1 Delirium 1

Interventions

relugolix 3 Uterine Myomectomy 3 Saline Solution 3 Misoprostol 3 Hysterectomy 3 dienogest 2 carbetocin 2 Uterine Artery Embolization 2 Tranexamic Acid 2 Tourniquets 2 Lidocaine 2 Hysteroscopy 2 Ascorbic Acid 2 ulipristal 1 telapristone acetate 1 remimazolam 1 ramosetron 1 pirfenidone 1 estradiol, norethindrone drug combination 1 Vasopressins 1 Triptorelin Pamoate 1 Tablets 1 Surveys and Questionnaires 1 Surgical Procedures, Operative 1 Sodium Chloride 1 Sevoflurane 1 Respiration, Artificial 1 Remifentanil 1 Propofol 1 Population Groups 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05025410 2022-04-25

Remimazolam and Remifentanil Without Neuromuscular Blocking Agent

Seoul National University Bundang Hospital

Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡